SAPIEN — Regulatory decision
September
The Centers for Medicare & Medicaid Services (CMS) continues to advance the reconsideration of the National Coverage Determination (NCD) for TAVR, with a final decision memo expected in September.Source filing
EW biotech catalysts & pipeline
EDWARDS LIFESCIENCES CORP · Data as of 2026-09-08
Upcoming catalysts
CLASP IITR trial — Conference presentation
Oct 31–Nov 3
Also in the fourth quarter, Edwards continues to expect CLASP IITR trial results to be presented at TCT, and the launch of the PASCAL system in the U.S. for tricuspid patients.Source filing
PROGRESS trial — Conference presentation
Oct 31–Nov 3
The clinical community will learn more about the clinical relevance of treating these patients with TAVR when the PROGRESS trial results are presented at TCT later this year.Source filing
SAPIEN TAVR — Conference presentation
Oct 31–Nov 3
Later this year, results of the PROGRESS trial studying patients with moderate AS will be presented at the TCT conference.Source filing